CLAIM #56632 · Thermo Fisher Scientific Inc (TMO) · 2026Q1 earnings call · Apr 23, 2026 · due Dec 31, 2026
“We estimate the full year average diluted share count will be between $370 million and 375 million shares.”
James Meyer · CFO
How to check this claim
Look at: Full year average diluted share count
It came true if: Between 370 million and 375 million shares
Where: Company income statement / 10-K annual report (diluted shares outstanding)
In context
“lent operational performance, enabling us to increase our guidance for the year while navigating a complex macro environment. Let me provide you some of the modeling elements for the full year. We expect approximately $660 million of net interest expense, which now includes financing for the Clario acquisition. We continue to assume that the adjusted income tax rate will be 11.5%. We expect between $1.9 billion and $2.1 billion of net capital expenditures and free cash flow in the range of $6.9 billion to $7.4 billion for the year, both reflecting the addition of Clario. In terms of capital deployment, we're assuming $3 billion of share buybacks, which were already completed in January and that we'll return approximately $700 million of capital to shareholders this year through dividends. We estimate the full year average diluted share count will be between $370 million and 375 million shares. Now let me provide some color on phasing for Q2. Aligned with the quarterly progression in our original guidance, we are assuming organic revenue growth of about 3% for the second quarter. We expect Q2 adjusted EPS to be between $0.25 and $0.30 higher than Q1. So to conclude, we had a strong quarter. We executed very well to deliver on our commitments. We are thrilled to have welcomed Clario to the company, and we are raising our adjusted EPS guidance for the year. With that, I'll turn the call back over to Raf. Rafael Tejada: Operator, we're ready for the Q&A portion of the call. Operator: [Operator Instructions] Our first question comes from Michael Ryskin from Bank of America. Michael Ryskin: Great. Marc, let me start with sort of a high-level one. A lot of questions from investors, bo”
Verify independently
SEC filings for TMO ↗ · Claim quote is verbatim from the 2026Q1 earnings call.